Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Gilead Sciences
Gilead Sciences
#JPM20: Vertex lays out post-CF ambitions as Gilead demurs on acquisition
Endpoints
Mon, 01/13/20 - 11:53 pm
Vertex Pharmaceuticals
cystic fibrosis
JPMHC 2020
Gilead Sciences
M&A
A Preview Of JPMorgan's Healthcare Conference: Focus On Value-Creating Themes, 2020 Expectations
Yahoo/Benzinga
Sat, 01/11/20 - 11:02 pm
JPMHC 2020
Bristol-Myers Squibb
Vertex Pharmaceuticals
Biomarin
Regeneron
Biogen
Alexion
Gilead Sciences
Amgen
GSK's plan to take over the HIV drug market hasn't worked out
BioPharma Dive
Mon, 01/6/20 - 11:47 pm
GSK
FDA
HIV
Dovato
Biktarvy
ViiV Healthcare
Gilead Sciences
Gilead gets ball rolling on JAKs game in Japan
Endpoints
Mon, 12/30/19 - 10:39 am
Gilead Sciences
Japan
filgotinib
Eisai
rheumatoid arthritis
As promised, Gilead and Galapagos file filgotinib to FDA and get a speedy review
Fierce Biotech
Fri, 12/20/19 - 12:29 pm
Gilead Sciences
FDA
filgotinib
Galapagos
rheumatoid arthritis
Pharma's gene and cell therapy ambitions will kick into high gear in 2020—despite some major hurdles
Fierce Pharma
Thu, 12/19/19 - 01:11 pm
gene therapy
reimbursement
drug manufacturing
Bristol-Myers Squibb
Pfizer
Biomarin
Sarepta Therapeutics
Gilead Sciences
CAR-T
As NASH shifts again, the focus remains on Genfit’s big readout
EP Vantage
Wed, 12/18/19 - 10:53 am
NASH
Genfit
elafibranor
Pfizer
Boehringer Ingelheim
Gilead Sciences
Poxel
Takeda
Intercept Pharma
Bristol-Myers wins $752 million in U.S. patent case against Gilead
Reuters
Fri, 12/13/19 - 09:09 pm
Bristol-Myers Squibb
Gilead Sciences
Kite Pharma
patents
Juno Therapeutics
Attorney misconduct allegations crop up in Johnson & Johnson, Gilead cases
Fierce Pharma
Fri, 12/13/19 - 12:13 pm
attorneys
JNJ
Gilead Sciences
Gilead's Kite files for FDA approval of second CAR-T therapy
Fierce Biotech
Thu, 12/12/19 - 11:27 am
Gilead Sciences
KTE-X19
mantle cell lymphoma
CAR-T
Kite Pharma
For an 'acquisitive' Gilead, 2020 will be key test for CAR-T plans
Biopharma Dive
Tue, 12/10/19 - 11:51 pm
M&A
Gilead Sciences
Kite
ASH: Gilead touts 'astounding' Yescarta survival results at 3 years
Fierce Pharma
Sun, 12/8/19 - 10:13 pm
Gilead Sciences
Yescarta
ASH2019
CAR-T
refractory large B-cell lymphoma
Activists seek to block a Gilead patent extension on a lucrative HIV drug
Stat
Fri, 12/6/19 - 09:52 am
Gilead Sciences
patents
HIV
activists
TAF
Gilead’s converting Truvada PrEP users to Descovy faster than expected: analyst
Fierce Pharma
Tue, 12/3/19 - 10:31 pm
Gilead Sciences
HIV
PrEP
Truvada
Descovy
Amarin for $20B? Novartis' MedCo deal drives fresh buyout rumors for Vascepa's maker
Fierce Pharma
Mon, 11/25/19 - 09:49 pm
Amarin
M&A
Novartis
Medicines Company
Gilead Sciences
Does Amarin Have a Dark Horse Suitor?
Motley Fool
Sun, 11/24/19 - 11:32 pm
Amarin
Vascepa
M&A
Gilead Sciences
Gilead CEO Daniel O'Day says company is in an 'acquisitive mode'
Stat
Wed, 11/20/19 - 10:43 pm
Gilead Sciences
Daniel O'Day
Pharma CEOs
M&A
Will Its HIV Lineup Save Gilead Sciences?
Motley Fool
Mon, 11/11/19 - 07:50 pm
Gilead Sciences
HIV
Descovy
Biktarvy
AASLD: Gilead wants to move the needle for fatty liver therapies
Fierce Biotech
Mon, 11/11/19 - 10:46 am
Gilead Sciences
NASH
selonsertib
clinical trials
AASLD
HHS sues Gilead for refusing to reach a licensing deal over patents for HIV prevention pills
Stat
Thu, 11/7/19 - 10:29 am
Gilead Sciences
HIV
HHS
Truvada
Descovy
Pages
« first
‹ previous
…
21
22
23
24
25
26
27
28
29
…
next ›
last »